Circassia Pharmaceuticals PLC

Circassia sets platform for strong growth in 2019 after period of consolidation

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), talks Proactive London's Andrew Scott through the group's 2018 results and the first quarter of this year.

Circassia's taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while its sales of its asthma product NIOX continued to grow.

They've also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.

Quick facts: Circassia Pharmaceuticals PLC

Price: £0.18

Market: LSE
Market Cap: £67.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...



Full interview: Circassia hires Pfizer exec as it continues transition to...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris caught up with Proactive London's Andrew Scott after news they've hired one of Pfizer’s top executives to become its first chief operating officer. Jonathan Emms, who has held a number of senior positions at both Pfizer and...

on 14/8/19


Holding(s) in Company

15 hours, 44 minutes ago

Holding(s) in Company

1 day, 15 hours ago

Holding(s) in Company

1 day, 16 hours ago

Holding(s) in Company

2 days, 20 hours ago

Holding(s) in Company

2 days, 21 hours ago

Holding(s) in Company

3 days, 16 hours ago

Block listing Interim Review

6 days, 15 hours ago

2 min read